English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In 2014, there were 480 000 new cases of multidrug-resistant tuberculosis (MDR-TB) around the world, but only 25% of them were diagnosed and reported. Drug resistance in TB is necessarily a laboratory diagnosis. An urgent priority in everyday practice is to diagnose tuberculosis and rule out drug resistance as quickly and as accurately as possible. However, worldwide, only 12% of new bacteriologically confirmed TB cases and 58% of previously treated TB cases were tested for drug resistance in 2014 .   New tools for diagnosis of TB and drug-resistant TB have been introduced for clinical practice during the past decade. Those new tools can detect and identify drug resistance to antituberculosis drugs in less than 24 hours, and they should be urgently integrated into clinical practice, especially in high-burden regions .   Ongoing transmission of TB generates new infections, and this infected population is the inexhaustible source of new TB cases. If we are really determined to stop the global TB epidemic, we need to treat active cases and also halt the transmission of the infection. The only strategy for preventing the development of active disease in individuals with subclinical infection is to give treatment for this latent infection .   Global control of TB requires a huge investment of funds to address current detection and treatment gaps. We must reconsider our current strategy and combine social components with biomedical interventions. This will require the development of alliances between government and civil society, as well as leadership and true political commitment at the highest level of government .

Clinical challenges in the era of multiple and extensively drugresistant tuberculosis